|Bid||3.8500 x 2200|
|Ask||4.1000 x 800|
|Day's Range||3.8200 - 4.0400|
|52 Week Range||1.6900 - 14.8300|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) shareholders should be happy to see the share price up 28% in the last...
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they underperformed ...
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 30.) Allergan plc (NYSE: AGN ) Arrowhead Pharmaceuticals ...
New biopharma startup Cyclerion Therapeutics has stumbled out of the gate, disclosing Wednesday that one of its lead drug candidates failed in a mid-stage study.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
A look at the shareholders of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) can tell us which group is most powerful...
Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
Joel Greenblatt (Trades, Portfolio)'s "You Can Be a Stock Market Genius" prompted many investors to follow spinoff stocks with close attention. Gurus like Peter Lynch, Charlie Munger (Trades, Portfolio) and Seth Klarman (Trades, Portfolio) do as well. Warning! GuruFocus has detected 1 Warning Sign with BCS.